http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer
-
Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer
-
Wave Life Sciences to Present at the 29th Annual Credit Suisse Healthcare Conference
-
Wave Life Sciences to Present at the 29th Annual Credit Suisse Healthcare Conference
-
Wave Life Sciences to Webcast Conference Call of Third Quarter 2020 Financial Results on November 9, 2020
-
Wave Life Sciences to Webcast Conference Call of Third Quarter 2020 Financial Results on November 9, 2020
-
Wave Life Sciences to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
-
Wave Life Sciences to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
-
Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
-
Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
-
Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
-
Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
-
Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update
-
Wave Life Sciences to Highlight PRISM Platform Advancements and Preclinical Neurology Pipeline During Analyst and Investor Research Webcast
-
Wave Life Sciences to Highlight PRISM Platform Advancements and Preclinical Neurology Pipeline During Analyst and Investor Research Webcast
-
Wave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020
-
Wave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020
-
Wave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference
-
Wave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference
-
Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery
-
Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery
-
Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
-
Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
-
Wave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020
-
Wave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
-
Wave Life Sciences to Present at the Cowen and Company 40th Annual Healthcare Conference
-
Wave Life Sciences to Present at the Cowen and Company 40th Annual Healthcare Conference
-
Wave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington’s Disease Program at CHDI Foundation’s 15th Annual HD Therapeutics Conference
-
Wave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington’s Disease Program at CHDI Foundation’s 15th Annual HD Therapeutics Conference
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020
-
WAVE Life Sciences (WVE) Reports Topline Data & Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial
-
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease
-
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease
-
WAVE Life Sciences (WVE) Announces Discontinuation of Suvodirsen Development for DMD
-
Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy
-
Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy
-
Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
-
WAVE Life Sciences (WVE) Announces Fast Track Designation from U.S. FDA for Suvodirsen
-
Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen
-
Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen
-
Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019
-
Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019
-
WAVE Life Sciences (WVE) Appoints Amy Pott, Heidi L. Wagner, JD, & Mark H. N. Corrigan, MD, to Board
-
Wave Life Sciences Expands Board of Directors with Three New Appointments
-
Wave Life Sciences Expands Board of Directors with Three New Appointments

